|
|
|
|
|
| Rubio,Fernando G.; Cunha,Clóvis A.; Lundgren,Fernando L.C.; Lima,Maria P.J.S.; Teixeira,Paulo J.Z.; Oliveira,Julio C.A.; Golin,Valdir; Mattos,Waldo L.L.D.; Mählmann,Herbert K.; Moreira,Edson D.; Jardim,Jose R.; Silva,Rodney L.F.; Silva,Patricia H.B.. |
| Community-Acquired Pneumonia (CAP) is a major public health problem. In Brazil it has been estimated that 2,000,000 people are affected by CAP every year. Of those, 780,000 are admitted to hospital, and 30,000 have death as the outcome. This is an open-label, non-comparative study with the purpose of evaluating efficacy, safety, and tolerability levels of IV azithromycin (IVA) and IV ceftriaxone (IVC), followed by oral azithromycin (OA) for the treatment of inpatients with mild to severe CAP. Eighty-six patients (mean age 56.6 ± 19.8) were administered IVA (500mg/day) and IVC (1g/day) for 2 to 5 days, followed by AO (500mg/day) to complete a total of 10 days. At the end of treatment (EOT) and after 30 days (End of Study - EOS) the medication was evaluated... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Community acquired infections; Pneumonia; Anti-bacterial agents; Macrolide ketolides; Azithromycin. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000300008 |
| |
|
|
|
